Multiple reports of unknown White dust / Particles falling out of the sky in West Virginia and Maryland

OK, I pulled up the flight radar for that location and I think the time is just after midnight UTC.

7:40 EST = 12:40 coordinated Universal time.

[link to mobile.flightradar24.com (secure)]

Might be N4864L?

Flying at 2500 ft elevation.

Landed at Martinsburg, Eastern West Virginia Regional AIrport

Tookoff at Hagerstown airport at 7:35 pm

Landed at Martinsburg, Eastern W Va Regional at around 8 pm.

Heading was 213 deg. ish? Not sure if that is magnetic or true that it reports.

No other small planes in the area at that time that I can see.

Pretty much has to be that plane.

Airport phone number is (304) 262-2507.

>>18402692

looks like that is an airforce or national guard airport with lots of heavy transport planes

Was just looking at the photos of the airport. About 6 - 8 heavy transports parked there.

Edit: 167th AIrlift National Guard.

C-17 Squadron.

>>18402755

Recall Pfizer is fulfilling a contract for the DOD/DARAP aka the US MILITARY

>>18402766

*DARPA

>>18402766

DARPA Hires Pfizer to Perform Groundbreaking Vaccine Research

https://www.yahoo.com/entertainment/2013-12-05-darpa-hires-pfizer-to-perform-groundbreaking-vacci.html

The Department of Defense announced eight defense contracts on Wednesday. Worth $198.4 million in total, the contracts ranged in value by a factor of 10 – from as much as $80 million to as little as $7.7 million. Yet it was that very smallest of the eight contracts awarded yesterday that was the most interesting.

The Defense Advanced Research Projects Agency (DARPA) awarded Pfizer a $7.7 million contract to research whether it might be possible to "identify and subsequently induce the production of protective antibodies to an emerging pathogen directly in an infected or exposed individual."

The traditional method of "curing" a disease from which DARPA is deviating involves extracting a pathogen, isolating its antigen, and using that antigen to create a vaccine in vitro. This vaccine is then injected into a patient to stimulate his or her immune system to fight off subsequent exposures to the pathogen. DARPA, however, appears to be tasking Pfizer with finding a shortcut, whereby all of this would happen in vivo, within the patient's body, thus dramatically cutting the time between the discovery of a pathogen and the military's ability to treat it. Incidentally, if Pfizer is successful in this work, its research could have significant applications in the civilian world as well.

Pfizer Awarded DARPA Biodefense Contract – DoD Daily Contracts

https://news.clearancejobs.com/2013/12/04/pfizer-awarded-darpa-biodefense-contract-dod-daily-contracts/

DEFENSE ADVANCED RESEARCH PROJECTS AGENCY

Pfizer, Inc., has been awarded a $7,670,632 technology investment agreement. Pfizer shall perform a research and development program designed to develop a technology platform to identify and subsequently induce the production of protective antibodies to an emerging pathogen directly in an infected or exposed individual. Work will be performed in Cambridge, Mass. The estimated completion date is Dec. 8, 2016. Fiscal 2013 research and development funds are being obligated at time of award. The contracting activity is the Defense Advanced Research Projects Agency, Arlington, Va., (HR0011-14-3-0001).

>>18402772

Then so too is the DOD and US Military.

The Defense Advanced Research Projects Agency (DARPA) is a research and developmentagency of the United States Department of Defenseresponsible for the development ofemerging technologies for use by the military.

Thus, "Military is the only way" should makee clear sense to all at this point. Military is the only way to A. execute the grandest of PsyOps via the media, NPO/NGO, and research elements of the MIC (military industrial complex), and B. rollout the genetic modification program under the Operation known as Warp Speed. No other way those executions are possible outside of military specttrum control and delivery.

Removing the Viral Threat: Two Months to Stop Pandemic X from Taking Hold(2017)

DARPA aims to develop an integrated end-to-end platform that uses nucleic acid sequences to halt the spread of viral infections in sixty days or less

Army General to Co-Lead 'Operation Warp Speed' for COVID-19 Vaccine

https://www.defense.gov/News/News-Stories/Article/Article/2188680/army-general-to-co-lead-operation-warp-speed-for-covid-19-vaccine/

>>18402810

>Army General to Co-Lead 'Operation Warp Speed' for COVID-19 Vaccine

You have accessed part of a historical collection on defense.gov. Some of the information contained within may be outdated and links may not function. Please contact the DOD Webmaster with any questions.

President Donald J. Trump today announced that Army Gen. Gustave F. Perna, the commander of Army Materiel Command, will co-lead an effort, dubbed Operation Warp Speed, to find a vaccine for COVID-19 by January 2021.

Men wearing face masks interact.

Defense Secretary Dr. Mark T. Esper said the Defense Department is very excited and committed to partnering with the Department of Health and Human Services, across the government, and in the private sector to accomplish the mission. "Winning matters, and we will deliver by the end of this year a vaccine at scale to treat the American people and our partners abroad," he said.

The goal is to produce about 300 million vaccines by January, said Jonathan Rath Hoffman, assistant to the secretary of defense for public affairs, at a Pentagon press briefing today.

Hoffman mentioned that it's a goal involving a whole-of-government approach, not just the DOD.

Play

Regarding DOD and the Pentagon, Hoffman said neither has been shut down and daily operations continue, albeit with mitigation steps that include social distancing, face masks, quarantine when necessary and telework if the situation allows.

As for increasing the number of personnel at the Pentagon, Hoffman said it will be conditions-based and informed by medical experts. The Pentagon, he said, is in consultation with the governments of the District of Columbia, Virginia and Maryland. Policy and decisions are currently under review and are expected to be released in a matter of weeks.

A man in a military uniform and face mask stands ready to distribute food packed in shopping bags.

Regarding the hospital ships USNS Comfort and Mercy, Hoffman said they have completed their work in New York City and Los Angeles and are standing by if their services are needed elsewhere.

Hoffman noted that tomorrow is Armed Forces Day. He mentioned the death yesterday of Army Staff Sgt. Ronald J. Shurer II, a Medal of Honor recipient.

Shurer served in Afghanistan. On April 6, 2008, he was cited for valorous actions for providing medical assistance to his teammates while facing enemy fire for over six hours.

Spotlight: Coronavirus: DOD Response Spotlight: Coronavirus: DOD Response: https://www.defense.gov/Explore/Spotlight/Coronavirus/

>>18402810

>Removing the Viral Threat: Two Months to Stop Pandemic X from Taking Hold(2017)

https://www.darpa.mil/news-events/2017-02-06a

DARPA aims to develop an integrated end-to-end platform that uses nucleic acid sequences to halt the spread of viral infections in sixty days or less

OUTREACH@DARPA.MIL

2/6/2017

Image caption: The Pandemic Prevention Platform (P3) program aims to develop an integrated platform that uses nucleic acid sequences to halt the spread of viral infections in sixty days or less. Using nucleic-acid-based technologies pioneered by DARPA as a foundation, the program now seeks to create an end-to-end platform by developing technologies to overcome remaining bottlenecks that hinder rapid response to pandemic threats. The three required technology areas cover growth of virus to support testing of treatments; rapid evolution of protective antibodies outside of the body; and safe and efficient delivery of nucleic-acid-based protective treatments.

Over the past several years, DARPA-funded researchers have pioneered RNA vaccine technology, a medical countermeasure against infectious diseases that uses coded genetic constructs to stimulate production of viral proteins in the body, which in turn can trigger a protective antibody response. As a follow-on effort, DARPA funded research into genetic constructs that can directly stimulate production of antibodies in the body.1,2 DARPA is now launching the Pandemic Prevention Platform (P3) program, aimed at developing that foundational work into an entire system capable of halting the spread of any viral disease outbreak before it can escalate to pandemic status. Such a capability would offer a stark contrast to the state of the art for developing and deploying traditional vaccines—a process that does not deliver treatments to patients until months, years, or even decades after a viral threat emerges.

“DARPA’s goal is to create a technology platform that can place a protective treatment into health providers’ hands within 60 days of a pathogen being identified, and have that treatment induce protection in patients within three days of administration. We need to be able to move at this speed considering how quickly outbreaks can get out of control,” said Matt Hepburn, the P3 Program Manager. “The technology needs to work on any viral disease, whether it’s one humans have faced before or not.”

Recent outbreaks of viral infectious diseases such as Zika, H1N1 influenza, and Ebola have cast into sharp relief the inability of the global health system to rapidly contain the spread of a disease using existing tools and procedures. State-of-the-art medical countermeasures typically take many months or even years to develop, produce, distribute, and administer. These solutions often arrive too late—if at all—and in quantities too small to respond to emerging threats. In contrast, the envisioned P3 platform would cut response time to weeks and stay within the window of relevance for containing an outbreak.

Key to this undertaking are nucleic-acid-based technologies—those that are centered on DNA and RNA—including some developed under DARPA’s Autonomous Diagnostics to Enable Prevention and Therapeutics (ADEPT) program. Using these tools, scientists can identify protective antibodies from recovering patients and then, through a biological version of reverse engineering, manufacture genetic constructs that, when delivered, can instruct an individual’s body to produce similar protective antibodies. Significant quantities of these nucleic acid “blueprints” can be rapidly manufactured compared to state-of-the-art antibody production methods.

What is required now are breakthroughs in three other technology areas to bridge those past DARPA achievements and overcome the remaining bottlenecks that hinder rapid response to pandemic threats. The P3 program will pursue innovations in those three areas:

Growing virus needed to support evaluation of therapies in laboratory tests;

Subjecting antibodies to rapid rounds of evolution outside of the body to increase their potency beyond that of even the most effective antibodies obtained from infected patients; and

Developing means of efficiently delivering nucleic-acid-based protective treatments, since the technologies used to administer conventional vaccines do not readily translate.

p1

>>18402819

Achieving and integrating breakthroughs in all of these areas will require choreographed cooperation among researchers and engineers specializing in such areas as immunology, microbiology, virology, medical infectious diseases, molecular biology, and medical countermeasure product development and manufacturing.

DARPA-funded teams will be required to demonstrate their integrated platforms in five simulations during the planned four-year program; they will initially test their platforms using pathogens of their choice, but ultimately they will test using DARPA-selected pathogens, including two demonstrations in which the identity of the pathogen will remain opaque to the teams until the 60-day clock starts. To ensure the developed platforms can produce a quality product with a viable pathway for regulatory review, each team will be required to complete a Phase I clinical safety trial before the end of the program.

A benefit of the nucleic-acid-based approach to limiting the spread of infection is that the genetic constructs introduced to the body would be processed quickly and would not integrate into an individual’s genome. Similarly, the antibodies produced in response to the treatment would only be present in the body for weeks to months. This is consistent with DARPA's intent with P3, which is to safely deliver transient immunity to a virus, halting the spread of disease by creating a firewall.

“Our country asks our military Service members to deploy globally and provide humanitarian assistance in all manner of high-risk environments. We owe it to them to develop the best protections possible,” said Hepburn, a U.S. Army physician who previously served as Director of Medical Preparedness on the White House National Security Staff. “If we’re successful, DARPA could take viral infectious disease outbreaks off the table as a threat to U.S. troops and as a driver of global instability.”

To further clarify the P3 program vision, answer questions from potential proposers, and facilitate teaming, DARPA is hosting two identical Proposers Days. The first will be at the Crown Plaza Tysons Corner McLean Hotel in McLean, Va., on February 22, 2017, and the second at the Doubletree by Hilton Hotel San Diego Downtown in San Diego on March 2, 2017. For registration information, visit: http://www.cvent.com/d/9vqy52.

Full details of the P3 program are included in a Broad Agency Announcement, available at: http://go.usa.gov/x9FbG. Proposal abstracts are due by 12:00 PM ET on March 13, 2017. Full proposals are due by 5:00 PM ET on May 1, 2017.

# # #

2 of 2

>>18402819

>>18402810

>pfizer AND moderna = US MILITARY

https://www.modernatx.com/partnerships/strategic-collaborators

DARPA

DARPA (Defense Advanced Research Projects Agency) is a research and development agency of the United States Department of Defense responsible for the development of emerging technologies for use by the military.

InOctober 2013, DARPA awarded Moderna up to approximately $25 million toresearch and develop potential mRNA medicinesto primarily support our vaccine and antibody programs to protect against Chikungunya infection.

DARPA Awards Moderna Therapeutics A Grant For Up To $25 Million To Develop Messenger RNA Therapeutics™

Research to focus on antibody production for immune defense

https://www.prnewswire.com/news-releases/darpa-awards-moderna-therapeutics-a-grant-for-up-to-25-million-to-develop-messenger-rna-therapeutics-226115821.html

CAMBRIDGE, Mass., Oct. 2, 2013 /PRNewswire/ – Moderna Therapeutics, the company pioneering messenger RNA therapeutics™, a revolutionary new treatment modality to enable the in vivo production of therapeutic proteins, announced today that the Defense Advanced Research Projects Agency (DARPA) has awarded the company up to $25 million to research and develop its messenger RNA therapeutics™ platform as a rapid and reliable way to make antibody-producing drugs to protect against a wide range of known and unknown emerging infectious diseases and engineered biological threats.

Messenger RNA therapeutics™ can be designed to tap directly into the body's natural processes to produce antibodies without exposing people to a weakened or inactivated virus or pathogen, as is the case with the vaccine approaches currently being tested. As a result, Moderna's messenger RNA therapeutics™ platform has the potential to speed the development and manufacture of treatments that can produce a safer, more reliable and more robust immune response than existing technologies.

p1

>>18402841

"We are honored to be chosen by DARPA for this important grant, which will greatly accelerate our efforts to develop antibody messenger RNA therapeutics™ to combat a wide range of infectious diseases," said Stephane Bancel, president and founding CEO of Moderna. "We were awarded this major grant after an intense and rigorous scientific review, and it is a testament to our team's progress and to the profound implications of messenger RNA therapeutics™ that our work was funded. We look forward to further expanding the development of our platform into this critically important new therapeutic area."

This $24.6 million grant could support research for up to 5 years to advance promising antibody- producing drug candidates into preclinical testing and human clinical trials. The company also received a $0.7 million "seedling" grant from DARPA in March to begin work on the project.

This grant is part of a DARPA program called ADEPT: PROTECT (Autonomous Diagnostics to Enable Prevention and Therapeutics: Prophylactic Options to Environmental and Contagious). The goal is to develop platform technologies that can be deployed safely and rapidly to provide the U.S. population with near-immediate protection against emerging infectious diseases and engineered biological weapons, even in cases when the pathogen or infectious agent is unknown.

About DARPA

The Defense Advanced Research Projects Agency (DARPA) is the primary innovation engine of the Department of Defense. DARPA is responsible for the development of new technologies for use by the military. To deliver on its mission, DARPA challenges the status quo and thinks outside of, and well beyond, prevailing perspectives. The Agency relies on diverse performers to apply multi-disciplinary approaches to advance knowledge through basic research and to create innovative technologies that address current practical problems through applied research. DARPA is a project based agency that sets challenging objectives with their grantees to achieve revolutionary capabilities. The agency's leadership regularly weighs the progress of each program in the context of their overall portfolio to make judgment calls to either redirect funding or to accelerate specific efforts.

About Moderna Therapeutics

Moderna is pioneering messenger RNA therapeutics™, an entirely new in vivo drug modality that produces human proteins or antibodies inside patient cells, which are in turn active intracellularly or secreted. This breakthrough platform addresses currently undruggable targets and offers a superior alternative to existing drug modalities for a wide range of disease conditions. Moderna has developed a broad intellectual property estate, including 144 patent applications with 6,910 claims ranging from novel nucleotide chemistries to specific drug compositions. The company plans to develop and commercialize its innovative mRNA drugs—initially for rare diseases and oncology—while partnering drug candidates in other therapeutic areas in order to rapidly deliver this innovation to patients. Moderna is a privately held company based in Cambridge, Massachusetts. Visit www.modernatx.com to learn more.

For information contact:

Dan Quinn

Feinstein Kean Healthcare

617-761-6732

dan.quinn@fkhealth.com

SOURCE Moderna Therapeutics

2 of 2

---—-

So either both Moderna AND Pfizer failed to deliver on their contracted milestones, objectives, goals, and deliverables, or they developed 'products' exactly to spec, request, and contractual agreement to the United States Military.

No other way this could have been done.

Key point to include is that the MEDIA is part of the MIC.

"A thesis similar to the military–industrial complex was originally expressed by Daniel Guérin, in his 1936 book Fascism and Big Business, about the fascist government ties to heavy industry. It can be defined as, "an informal and changing coalition of groups with vested psychological, moral, and material interests in the continuous development and maintenance of high levels of weaponry, in preservation of colonial markets and in military-strategic conceptions of internal affairs."[42] An exhibit of the trend was made in Franz Leopold Neumann's book Behemoth: The Structure and Practice of National Socialism in 1942, a study of how Nazism came into a position of power in a democratic state.

Within decades of its inception, the idea of the military–industrial complex gave rise to other similar industrial complexes, including the animal–industrial complex, prison–industrial complex, pharmaceutical–industrial complex, entertainment-industrial complex, and medical–industrial complex.[43]: ix–xxv  Virtually all institutions in sectors ranging from agriculture, medicine, entertainment, and media, to education, criminal justice, security, and transportation, began reconceiving and reconstructing in accordance with capitalist, industrial, and bureaucratic models with the aim of realizing profit, growth, and other imperatives. According to Steven Best, all these systems interrelate and reinforce one another.[43]

The concept of the military–industrial complex has been expanded to include the entertainment and creative industries as well. For an example in practice, Matthew Brummer describes Japan's Manga Military and how the Ministry of Defense uses popular culture and the moe that it engenders to shape domestic and international perceptions.[44]

An alternative term to describe the interdependence between the military-industrial complex and the entertainment industry is coined by James Der Derian as "Military-Industrial-Media-Entertainment-Network"."

https://en.wikipedia.org/wiki/Military%E2%80%93industrial_complex

>>18402885

US MIL = DOD = DARPA